Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen
TRANSPLANTATION PROCEEDINGS, vol.38, no.2, pp.496-498, 2006 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 38 Issue: 2
- Publication Date: 2006
- Doi Number: 10.1016/j.transproceed.2005.12.047
- Journal Name: TRANSPLANTATION PROCEEDINGS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.496-498
- Acibadem Mehmet Ali Aydinlar University Affiliated: No
Abstract
Background. There are numerous recent reports on the use of lamivudine for hepatitis B virus (HBV) infection after renal transplantation. However, the optimal strategy (prophylactic, preemptive, or salvage approach) for starting lamivudine treatment in this patient group has not been determined. The aim of this study was to assess how the timing of lamivudine therapy affected the HBV serological status and the transaminase levels in renal allograft recipients with chronic HBV infection.